Pharmaceutical Patent Strategy Seminar

　　On April 18, 2018, the "Patent Strategy Seminar in the Pharmaceutical Field" was held at Haibu Pharmaceutical, co-hosted by Haibu Pharmaceutical, TipLab, and Tongchuang Weiye. More than twenty founders and core executives from pharmaceutical companies engaged in drug research and development, medical device research and development, intellectual property management, and investment participated in this seminar.

　　The seminar was honored to invite Dr. Zhang Zheng as the keynote speaker. Dr. Zhang graduated from Tsinghua University and obtained a master's degree in intellectual property from ETH Zurich and a Ph.D. in molecular biology from the University of Zurich. Based on his own work experience, Dr. Zhang shared and discussed topics such as "the essence of patents, the special significance of patents for pharmaceutical companies, and the strategies for patent protection." He elaborated on the full lifecycle management and layout of intellectual property from multiple dimensions including blockbuster drug protection, patent strategies, patent disputes, and patent challenges. He also conducted case analyses from early-stage research to product development to post-market patent strategies.

　　During the seminar, participants exchanged views with Dr. Zhang on their understanding and doubts about patent protection, issues encountered during their company's R&D process related to patents, patent application issues, determination of patent infringement and defenses against it, as well as how to approach patent challenges to avoid infringement. Dr. Zhang analyzed these issues with practical cases which led to in-depth discussions that deepened everyone's understanding of patents.

　　Today, intellectual property protection is increasingly valued by enterprises, especially in technology-intensive companies where intellectual property is a powerful weapon determining strategic development. Haibu Pharmaceutical is a technology-driven enterprise focused on R&D; new processes, methods, and ideas are constantly emerging. How to effectively protect its intellectual property and maintain corporate value is crucial for its development. At the same time, generic drug R&D is one of Haibu Pharmaceutical's main businesses; domestic clinical products urgently needed are restricted by foreign original research patent protections that prevent other companies from replicating them during the protection period. Successfully challenging these patents to break through original research technical barriers is extremely significant for enabling Chinese people to access urgently needed clinical medications sooner.

　　[TipLab Introduction]

　　TipLab is a cutting-edge research consulting company in China focused on strategic management of knowledge assets. Based on systematic in-depth research into innovative technology fields—especially cutting-edge areas like healthcare, life sciences, artificial intelligence—TipLab helps technology-driven enterprises gain and maintain competitive advantages through strategic knowledge asset management using unique computer-assisted systems.

　　[Haibu Pharmaceutical Introduction]

　　Beijing Haibu Pharmaceutical Technology Co., Ltd (stock abbreviation: Haibu Pharmaceutical; stock code: 836438) was established in 2005 in Beijing Economic-Technological Development Area as a high-tech enterprise focusing on chemical drug R&D with a global perspective. The company mainly engages in R&D, production, sales of chemical raw materials drugs, pharmaceutical intermediates, drug formulations as well as technology transfer and technical services; it has two wholly-owned subsidiaries: Beijing Haimeitong and Beijing Haimeiyuan.

　　Haibu Pharmaceutical has over 4,000 square meters of laboratory space with nearly 200 R&D team members; those with master's degrees or higher account for 32%. It is equipped with conventional instruments related to chemical synthesis, formulation analysis along with high-end equipment ranging from small-scale trials to pilot-scale production providing ample support for high-quality R&D work across multiple fields including anti-tumor drugs, depression treatments cardiovascular drugs digestive system respiratory system medications achieving numerous research results.

　　[Tongchuang Weiye Introduction]

　　Tongchuang Weiye is one of China's first professional private equity investment firms with 17 years of asset management experience ranking among the industry's leaders in asset management scale. The company has long focused on investing in entrepreneurial enterprises being a leading local brand professional investment institution known for its long operational history and consistently excellent returns.